ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Clinical Infectious Diseases
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1593228
This article is part of the Research TopicExploring Clinical Application Scenarios of Metagenomic Next-Generation Sequencing for Pathogen DiagnosisView all 7 articles
The Application Value of Targeted Next-Generation Sequencing in the Diagnosis of Primary Osteoarticular Infections: A Single-Center Study
Provisionally accepted
- 1Ningxia Medical University, Yinchuan, Ningxia, China
- 2General Hospital of Ningxia Medical University, Yinchuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To evaluate the diagnostic performance and clinical utility of targeted next-generation sequencing (tNGS) in primary osteoarticular infections (POI). Methods: Eighty-seven patients diagnosed with POI at the Bone Infection Ward of Ningxia Medical University General Hospital between September 2023 and September 2024 were enrolled, including cases of tuberculous osteoarticular infection (35 cases), Brucella-related osteoarticular infection (21 cases), and pyogenic osteoarticular infection (31 cases). Using bacterial culture, Xpert MTB/RIF assay, Brucella agglutination test, and histopathological examination as reference standards, the diagnostic value of tNGS in pathogen identification and resistance gene analysis was systematically evaluated. Results: All patients had complete follow-up data. The cohort comprised 87 POI patients (mean age: 55.36 ± 17.24 years; male-to-female ratio: 1.35:1). tNGS demonstrated significantly higher overall sensitivity than conventional bacterial culture (85.0% vs. 31.0%, P < 0.001). For resistance profiling, tNGS identified Mycobacterium tuberculosis complex mutations associated with resistance to isoniazid (2 cases), rifampicin (2 cases), ethambutol (1 case), pyrazinamide (5 cases), and streptomycin (1 case). Additionally, one fluoroquinolone resistance gene and one extended-spectrum β-lactamase (ESBL)-producing pathogen were detected. Notably, one multidrug-resistant (MDR) case harbored mutations conferring resistance to five anti-tuberculosis agents. Receiver operating characteristic (ROC) curve analysis revealed that tNGS exhibited superior diagnostic accuracy for tuberculous osteoarticular infections (AUC = 0.926), Brucella-related osteoarticular infections (AUC = 0.891), and pyogenic osteoarticular infections (AUC = 0.912), outperforming Xpert MTB/RIF (0.814), Brucella agglutination test (0.832), bacterial culture (0.652), and histopathology (0.704) (all P < 0.05). Conclusion: tNGS enables simultaneous pathogen identification and resistance gene detection with high efficiency, broad coverage, and accuracy, demonstrating significant advantages in POI diagnosis. This technology holds critical value in guiding optimized antimicrobial therapy and is recommended as a first-line molecular diagnostic tool for POI.
Keywords: Targeted next-generation sequencing (TNGS), Primary osteoarticularinfection (POI), diagnostic value, Pathogen Detection, Drug resistance gene
Received: 13 Mar 2025; Accepted: 04 Sep 2025.
Copyright: © 2025 陶, Zhu, Shi, Yang and Niu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ningkui Niu, General Hospital of Ningxia Medical University, Yinchuan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.